Best Small Cell Carcinoma Podcasts (2025)

1
Dermatologic Adverse Event Mitigation and Management Strategies with Amivantamab + Lazertinib Therapy for Advanced Non-Small Cell Lung Cancer 23:31

Play Pause

1d ago23:31

23:31

In this podcast, Dr. Danny Nguyen from the City of Hope, Huntington Beach, CA, USA, and Dr. Edgardo S. Santos from the Oncology Institute of Hope and Innovation, Broward County, FL, USA, aim to educate on strategies to mitigate and manage dermatologic adverse events associated with amivantamab + lazertinib. This podcast is published open access in …

1
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities 35:15

24d ago35:15

35:15

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including: Key Comorbidit…

1
Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion 38:07

1M ago38:07

38:07

· In this podcast, the authors discuss the current therapeutic landscape of NSCLC with actionable alterations and provide their perspectives on treatment algorithms, and how to optimally sequence therapies for patients with tumors harboring actionable alterations, using patient cases to illustrate key principles. This podcast is published open acce…

1
Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications 21:54

1M ago21:54

21:54

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers. Toxicity Profiles of HER2-Targeted ADCs: Common and…

1
Increasing Awareness of Soft-Tissue Sarcoma: Podcast of a Patient–HCP Discussion 40:34

1M ago40:34

40:34

· In this podcast a patient with sarcoma and a specialist sarcoma nurse discuss the patient’s journey from initial diagnosis through to treatment and recovery. They will also discuss the physiological, emotional and mental impact that sarcoma had, as well as the critical role of the cancer nurse specialist within the treatment plan, alongside a pat…

1
Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies 29:36

2M ago29:36

29:36

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, explore the mechanisms of HER2-targeted antibody–drug conjugates (ADCs) and emerging clinical data with these agents across genitourinary, gastrointestinal, and gynecologic cancers. Mechanisms of action of ADCs: how ADCs selective…

1
Burnout Among Physicians Treating Patients with Multiple Sclerosis in the United States: A Podcast 13:52

2M ago13:52

13:52

A podcast focusing on burnout among physicians that treat patients with multiple sclerosis. This podcast is published open access in Neurology and Therapy and is fully citeable. You can access the original published podcast article through the Neurology and Therapy website and by using this link: Burnout Among Physicians Treating Patients with Mult…

1
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer 18:34

2M ago18:34

18:34

In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3 Overview of the structure of antibody-drug conjugates (ADCs) Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-…

1
The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies 14:09

2M ago14:09

14:09

In this episode, Zev A. Wainberg, MD; Funda Meric-Bernstam, MD; Alexandra Leary, MD, PhD; and Catherine Fahey, MD, PhD, explore testing for HER2 alterations and the incidence of HER2-positive disease in the treatment of genitourinary, gastrointestinal, and gynecologic malignancies. HER2 Testing in Advanced Cancers: Recommendations for when and how …

1
Shared Decision-Making for Advanced Renal Cell Carcinoma: Focus on Adverse Event Management of Axitinib Plus IO: A Vodcast 31:04

3M ago31:04

31:04

Shared decision-making is essential to the care of patients with advanced renal carcinoma which can empower patients and help the healthcare team understand the patient’s goals of care. Identification and management of treatment-related adverse events is key to this. In this podcast, a patient author and two healthcare professionals with real-world…

1
Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC 14:42

3M ago14:42

14:42

In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including: Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastu…

1
CIBMTR Registry Data on Inotuzumab Ozogamicin Treatment in Patients with ALL Who Proceeded to Hematopoietic Stem Cell Transplant—A Podcast 18:24

3M ago18:24

18:24

In this podcast, Dr. Marcos de Lima from the Ohio State University, Columbus, OH, USA, and Dr. David I. Marks from the University Hospitals Bristol NHS Trust, Bristol, UK, discuss real-world data obtained from the Center for International Blood and Marrow Transplant Research database to evaluate post-allogeneic hematopoietic stem cell transplantati…

1
Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer 45:08

4M ago45:08

45:08

In this episode, Jame Abraham, MD, FACP; William J. Gradishar, MD, FACP, FASCO; and Laura Spring, MD, review key insights and frequently asked questions related to the CDK4/6 inhibitors used to treat patients with early and metastatic hormone receptor (HR)–positive/HER2-negative breast cancer from a live program held in January 2025. Key clinical p…

1
Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting 20:01

4M ago20:01

20:01

In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including: Early results with teclistamab combined with anti-CD38 therapy Real-world data with teclistamab including its use aft…

1
Rhythms of Healing: Patient and Physician Insights on Art, Music, Dance Therapy and Creativity in Parkinson's Disease 33:20

5M ago33:20

33:20

A podcast to provide an insight in to how art, music, dance therapy and creativity can help alleviate the symptoms of Parkinson's Disease. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any …

1
Bosutinib for the Treatment of CML—Using it Safely: a Podcast 29:41

5M ago29:41

29:41

In this podcast, Dr. Jeffrey H. Lipton, from the Princess Margaret Cancer Centre, Toronto, ON, Canada, and Dr. Jorge E. Cortes from the Georgia Cancer Centre, Augusta, GA, USA, summarize data from some recent bosutinib publications and discuss implications for optimizing bosutinib treatment of patients with CML. This podcast is published open acces…

1
Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer 36:04

5M ago36:04

36:04

In this episode, listen to Virginia Kaklamani, MD, DSc; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, share their clinical insights and takeaways from a live symposium, including from key abstracts presented at the 2024 San Antonio Breast Cancer Symposium: Estrogen receptor mutations in patients With HR-positive/HER2-negative advanced breast ca…

1
A Podcast on Patient and Physician Perspectives in the Holistic Care of Heart-Related Challenges of Type 2 Diabetes 23:43

6M ago23:43

23:43

This podcast is published open access in Diabetes Therapy and is fully citeable. You can access the original published podcast article through the Diabetes Therapy website and by using this link: https://link.springer.com/article/10.1007/s13300-024-01669-5. All conflicts of interest can be found online. This podcast is intended for medical professi…

1
A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases 48:51

6M ago48:51

48:51

The incidence of brain metastases is higher in patients with non-small cell lung cancer (NSCLC) than in patients with most other cancers, and the development of brain metastases is associated with poor prognosis. The objective of the podcast is to provide information about current and future treatments for brain metastases that develop in patients …

1
Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) DLBCL with CAR T Cell Therapy: A Vodcast and Case Example 18:36

6M ago18:36

18:36

Authors Gloria Iacoboni and María Pérez Raya outline the management of a patient receiving Chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL). CAR T-cell therapy is effective in the treatment of patients with DLBCL, even those with high-grade disease. However, it has a unique safety pr…

1
Patient and Physician Perspectives of Diabetic Retinopathy and Diabetic Macular Edema Diagnosis, Treatment and Progression: A Podcast Article 37:46

8M ago37:46

37:46

This podcast is published open access in Ophthalmology and Therapy and is fully citeable. You can access the original published podcast article through the Ophthalmology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40123-024-01053-3 All conflicts of interest can be found online. This podcast is intended for…

1
A Podcast on Patient and Physician Perspectives on Management and a New Medical Therapy (Relugolix Combination Therapy) 23:21

8M ago23:21

23:21

In this podcast, a reproductive endocrinologist (Dr Sanjay K Agarwal) and patient advocate (Tara Mangum) provide their perspectives on the diagnosis and management of endometriosis. They also discuss Relugolix combination therapy as a treatment option for patients with endometriosis. This podcast is published open access in Advances in Therapy and …

1
Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies 20:40

8M ago20:40

20:40

In this episode, Caitlin Costello, MD, discusses important topics related to relapsed/refractory (R/R) multiple myeloma (MM), including: 3 bispecific antibodies approved for the treatment of R/R MM that target BCMA or GPRC5D The role of bispecific antibodies in R/R MM Safety considerations for patients while receiving a bispecific antibody Emerging…

1
Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations 28:28

8M ago28:28

28:28

In this episode, Thor R. Halfdanarson, MD, and Jonathan Strosberg, MD, discuss important topics related to gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including: The diagnosis and typical presenting symptoms of GEP-NETs Findings from recent key phase III studies including NETTER-2 and CABINET Recommendations for treatment sequencing No…

1
Physician Perspectives on the Management of Patients with Resected High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck Who Are Ineligible to Receive Cisplatin: A Podcast 41:52

8M ago41:52

41:52

In this podcast, Dr. Robert I. Haddad, from the Dana-Farber Cancer Institute in Boston, MA, USA, and Dr. Kevin Harrington from the Royal Marsden NHS Foundation Trust in London, UK, share their clinical experience and provide their perspectives related to cisplatin ineligibility in patients with locally advanced squamous cell carcinoma of the head a…

1
Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast 46:25

9M ago46:25

46:25

In this episode, two experts in the field of kidney cancer, Dr Benjamin Garmezy and Dr Vaishampayan, will present hypothetical case studies that represent typical patients seen with advanced renal cell carcinoma (aRCC) in practice. The faculty will discuss treatment approaches, adverse event management, and which factors to consider during the trea…

1
ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers 30:45

9M ago30:45

30:45

In this episode, listen to Ana Oaknin, MD, PhD and Alexandra Leary, MD, PhD, share their clinical insights and takeaways on key updates and new data presented for ovarian, endometrial, and cervical cancer at the ESMO 2024 annual congress including: Phase III PRIMA/ENGOT-OV26/GOG-3012 Final OS Results: Niraparib as First-Line Maintenance in Advanced…

1
A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance 32:48

9M ago32:48

32:48

In this episode, listen to Matthew S. Davids, MD, MMSc, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including: Contemporary treatment paradigms for patients with CLL Safety and efficacy of current regimens Molecular testing, including when and how to test for BTK inhibitor res…

1
Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC 13:53

10M ago13:53

13:53

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including: Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advan…

1
Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC 13:46

10M ago13:46

13:46

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including: Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLC Long-term safety observations for cri…

1
ROS1-Alterations and Molecular Testing in Advanced NSCLC 16:28

10M ago16:28

16:28

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including: ROS1-gene fusions in advanced lung cancer ROS1 testing recommendations with DNA …

1
Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers 49:32

11M ago49:32

49:32

In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including: RUBY Part 1 Subgroup …

1
Podcast: Need for Quality Evidence for Decision-Making on Seasonal Influenza Vaccines 24:04

11M ago24:04

24:04

This podcast is published open access in Infectious Diseases and Therapy and is fully citeable. You can access the original published podcast article through the Infectious Diseases and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40121-024-00932-3. All conflicts of interest can be found online. This podcast is…

1
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs 34:45

11M ago34:45

34:45

In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer. Presenters: Virginia Kaklamani, MD, DSc Prof…

1
Current Clinical Practice and NCCN Guidelines for CLL/SLL 31:33

11M ago31:33

31:33

In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including: Prognostic variables when deciding between regimens Role of MRD in CLL Results from the phase II CAPTIVATE trial Choosing among th…

1
A Podcast on Practical Considerations in Patients with Advanced Urothelial Cancer Receiving First-Line Cisplatin- or Carboplatin-Based Chemotherapy Followed by Avelumab Maintenance in a Changing Therapeutic ... 25:05

11M ago25:05

25:05

In this podcast, authors discuss the evolving role of platinum-based chemotherapy in patients with advanced urothelial cancer in the context of EV-302 trial results and describe practical considerations in patients receiving first-line cisplatin- or carboplatin-based chemotherapy followed by avelumab maintenance therapy. This podcast is published o…

1
Congress to Clinic: Expert Takeaways on Emerging Data for MPNs 28:35

12M ago28:35

28:35

In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including: Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the M…

1
CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways 24:23

12M ago24:23

24:23

In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including: Rationale for targeting CELMoDs in NHL Mechanism of action of CELMoDs Key studies and available efficacy and safety data with investigational CELMoDs in NHL Key ongoing clinical trials of CELMoDs in NHL Strategies to…

1
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer 24:30

12M ago24:30

24:30

In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include: Evidence from the monarchE and NATALEE trials of adjuvant abemacicli…

1
Congress to Clinic: Expert Takeaways on Emerging Data for AML 25:21

12M ago25:21

25:21

In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractor…

1
Congress to Clinic: Expert Takeaways on Emerging Data for MDS 19:19

12M ago19:19

19:19

In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low…

1
A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma 48:30

12M ago48:30

48:30

In this podcast, Shilpa Gupta from the Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Helen H.-S. Moon from the Kaiser Permanente Riverside Medical Center, Riverside, CA, and Srikala S. Sridhar from the Princess Margaret Cancer Centre, University Health Network, Toronto, Canada discus recent developments in the treatment landscape for ad…

1
205 - Empowerment in Midlife: Revealing Your Potential with Joe Hoye 26:09

1y ago26:09

26:09

Explore the key components of designing your ideal life. Host Amy Ledin introduces Joe Hoye, a renowned fitness expert spearheading a summit on perimenopause, menopause, and overall well-being. Joe shares his transformative journey, ignited at age 13 by his mother's introduction to the gym, propelling him into a career in surgical technology with a…

1
204 - Six Reasons You Should Rehearse Your Day 13:54

1y ago13:54

13:54

Discover how a simple five-minute nightly routine can transform your day with reduced stress and heightened efficiency. Host Amy Ledin shares personal insights and actionable strategies for implementing this practice, emphasizing the benefits of detailed planning for daily tasks and nutrition. She explains how mentally rehearsing your day can help …

1
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer 25:55

1y ago25:55

25:55

In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast canc…

1
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 47:23

1y ago47:23

47:23

In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses: Optimal selection of therapy for treatment-naive CLL, includin…

1
203 - A Mother's Love Beyond Loss 43:28

1y ago43:28

43:28

Embark on a journey of understanding, solace, and resilience as we explore grief, faith, and the human spirit. Host Amy Ledin graciously welcomes Sarah Prebianca to the podcast. Together, they have unraveled Sarah's remarkable story—a testament to resilience in the face of unimaginable loss, her daughter Georgia taken by a rare disease. Through Sar…

1
202 - What I Eat In A Week 34:28

1y ago34:28

34:28

Forget about the generic "What I Eat in a Day" posts flooding your social media feeds. Amy Ledin breaks away from the norm, revealing the intricacies of her weekly meal plans, complete with recipes, grocery lists, and strategic advice. Amy delves into the significance of meal timings, managing portions, and embracing mindful eating, giving you a pe…

1
Podcast on the IWGDF 2023 Guidelines on the Prevention of Foot Ulcers in Persons with Diabetes 7:51

1y ago7:51

7:51

In this podcast, the Chair and Secretary of the 2023 International Working Group on the Diabetic Foot (IWGDF) guideline on prevention for diabetes-related foot ulcers. This podcast aims to highlight the importance of ulcer prevention and the opportunities to incorporate recommendations into clinical practice. This podcast is published open access i…

1
Podcast on Emerging Treatment Options for Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors 23:28

1y ago23:28

23:28

Anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT) are rare cancers observed predominantly in children and young adults. ALCL accounts for 10–15% of all pediatric non-Hodgkin lymphomas and is commonly diagnosed at an advanced stage of disease. This podcast provides an overview of ALK-positive ALCL and IMT. The author…